REPLIMUNE GROUP INC (REPL)       25.89  -0.24 (-0.92%)

25.89  -0.24 (-0.92%)

US76029N1063 - Common Stock - After market: 25.89 0 (0%)

REPLIMUNE GROUP INC25.89

NASDAQ:REPL (1/27/2023, 7:00:02 PM)-0.24 (-0.92%)

After market: 25.89 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-03 2022-11-03/bmo Earnings (Next) 02-01 2023-02-01
Ins Owners 18.54% Inst Owners 82.97%
Market Cap 1.29B Shares 49.74M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 86.67
IPO 07-20 2018-07-20

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

REPL Daily chart

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 206 full-time employees. The company went IPO on 2018-07-20. The firm is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The firm's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The firm's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathway activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Company Info

REPLIMUNE GROUP INC

500 Unicorn Park Dr

Woburn MASSACHUSETTS 01801

P: 17812229600.0

CEO: Philip Astley-Sparke

Employees: 206

Website: https://www.replimune.com/

REPL News

News Image24 days ago - Replimune Group IncReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

News Image25 days ago - Replimune Group IncReplimune to Present at the 41st Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...

News Image2 months ago - Replimune Group IncReplimune Announces Pricing of Public Offering

BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a...

News Image2 months ago - Replimune Group IncReplimune Announces Proposed Public Offering

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a...

News Image2 months ago - Seeking AlphaREPL stock on watch after deal with Roche to study cancer drug combos (NASDAQ:REPL)

Replimune Group (REPL) announced a collaboration with Roche (RHHBY) (RHHBF) on Wednesday to study combination therapies for cancer. Read the full story here.

News Image2 months ago - Replimune Group IncReplimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma Overall response rate (ORR) of...

REPL Twits

Here you can normally see the latest stock twits on REPL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example